Literature DB >> 303056

Altered schistosome granuloma formation in nude mice.

J E Byram, F von Lichtenberg.   

Abstract

Schistosome egg-induced lesions in congenitally athymic mice differed from those found in normal heterozygous controls. Heterozygote liver granulomas were chareacterized by poorly phagocytic epithelioid macrophages, and were rich in eosinophils and fibroblasts, with peripheral lymphocytes and plasma cells. Hepatic lesions in nude mice were much smaller and lacked epithelioid macrophages, with lesions about mature eggs, typically consisting of monocytes and macrophages filled with pigment, occasional neutrophils, and rarely one or more eosinophils or giant cells. While heterozygote granulomas damaged liver cells mainly by encroachment or by their vascular effects, in the nudes hepatocytes bordering the lesions showed microvesicular cytoplasmic damage and either hydropic degeneration or focal acidophilic necrosis of individual liver cells. In heterozygotes, immunofluorescent-stainable schistosome egg antigen (SEA) was concentrated in the granuloma center. In nude mice, SEA, was distributed throughout the infiltrates and in and around hepatocytes adjacent to egg lesions corresponding to the observed pattern of hepatocyte necrosis. We conclude that, in contrast to heterozygotes, nude mice lack hypersensitivity granulomas and fail to sequester toxic egg products, this resulting in zonal hepatocellular damage. Alternative explanations include the possibility of a latent hepatitis virus being activated by the schistosome infection; however, several cogent arguments are presented against that alternative.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 303056     DOI: 10.4269/ajtmh.1977.26.944

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  25 in total

1.  Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin-2 production in Schistosoma mansoni infection.

Authors:  R C Mathew; D L Boros
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

2.  Serum Carbonic Anhydrase 1 is a Biomarker for Diagnosis of Human Schistosoma mansoni Infection.

Authors:  Manal Ibrahim Kardoush; Brian J Ward; Momar Ndao
Journal:  Am J Trop Med Hyg       Date:  2017-04       Impact factor: 2.345

Review 3.  Effector cells, molecules and mechanisms in host-protective immunity to parasites.

Authors:  G F Mitchell
Journal:  Immunology       Date:  1979-10       Impact factor: 7.397

Review 4.  Immunopathology of Schistosoma mansoni infection.

Authors:  D L Boros
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

5.  Presence of Schistosoma mansoni antigens in liver, spleen and kidney of infected mice: a sequential study.

Authors:  I El-Dosoky; E A Van Marck; A M Deelder
Journal:  Z Parasitenkd       Date:  1984

6.  Potentiation of schistosome granuloma formation. By lentinan--a T-cell adjuvant.

Authors:  J E Byram; A Sher; J DiPietro; F von Lichtenberg
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

7.  Epithelioid granuloma formation requiring no T-cell function.

Authors:  A Tanaka; K Emori; S Nagao; K Kushima; O Kohashi; M Saitoh; T Kataoka
Journal:  Am J Pathol       Date:  1982-02       Impact factor: 4.307

8.  Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni.

Authors:  L Abel; F Demenais; A Prata; A E Souza; A Dessein
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

9.  Etiology of the liver granulomatous response in Schistosoma mansoni-infected athymic nude mice.

Authors:  A F Amsden; D L Boros; A T Hood
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

10.  Activity of artemether and mefloquine against juvenile and adult Schistosoma mansoni in athymic and immunocompetent NMRI mice.

Authors:  Jennifer Keiser; Mireille Vargas; Michael J Doenhoff
Journal:  Am J Trop Med Hyg       Date:  2010-01       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.